- Home
- CNSP vs NDRA Comparison
CNSP vs NDRA Comparison
Compare CNSP & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNSP | NDRA |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.5M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CNSP | NDRA |
|---|---|---|
| Price | $4.96 | $5.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $20.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 2.1M | 13.8K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.03 | ★ 84.32 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $2.92 |
| 52 Week High | $10.59 | $11.91 |
Technical Indicators
Market Signals| Indicator | CNSP | NDRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 50.80 |
| Support Level | $2.01 | $5.08 |
| Resistance Level | $8.56 | $5.36 |
| Average True Range (ATR) | 0.97 | 0.40 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 32.95 | 33.99 |
Price Performance
Historical ComparisonAbout CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.